Cargando…
Interstitial Lung Disease Induced by Pazopanib Treatment
Although pneumothorax has been reported to be a major pulmonary adverse event in patients treated with pazopanib, a multikinase inhibitor, drug-induced interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese man who received pazopanib for the treatment of femoral leiomyosarcom...
Autores principales: | Ide, Shotaro, Sakamoto, Noriho, Hara, Shintaro, Hara, Atsuko, Kakugawa, Tomoyuki, Nakamura, Yoichi, Futsuki, Yoji, Izumikawa, Koichi, Ishimatsu, Yuji, Yanagihara, Katsunori, Mukae, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313429/ https://www.ncbi.nlm.nih.gov/pubmed/28050004 |
Ejemplares similares
-
Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018) -
Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis
por: Sakamoto, Noriho, et al.
Publicado: (2015) -
Serum heat shock protein 47 levels are elevated in acute interstitial pneumonia
por: Kakugawa, Tomoyuki, et al.
Publicado: (2014) -
Interstitial Pneumonia with HLA-B54 Antigen that Responded Well to Erythromycin
por: Ishimoto, Hiroshi, et al.
Publicado: (2022) -
Pulmonary Alveolar Proteinosis with Ulcerative Colitis
por: Sakamoto, Noriho, et al.
Publicado: (2018)